13. The use according to any one of claims 1 to 12, wherein said fungal ~~infection~~ keratitis is caused by a fungi from the genus group of *Candida or Aspergillus*.

14. The use according to claim 13, wherein the fungi is selected from the group consisting of *Candida albicans*, *Aspergillus fumigatus*, *Aspergillus flavus*, *Aspergillus clavatus*, and *Aspergillus niger*.

15. The use according to claim 14, wherein the fungi is *Candida albicans*.

16. The use according to claim 14, wherein the fungi is *Aspergillus niger*.

17. The use according to any one of claims 1 to 16, wherein the minimum inhibition concentration of said compound in said medicament is in the range of 10 to 130 ppm.

18. The use according to claim 13, wherein said fungi is present as a biofilm.